{"id":"NCT02569996","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma","officialTitle":"A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2015-10-07","resultsPosted":"2015-12-10","lastUpdate":"2015-12-10"},"enrollment":124,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Follicular"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["MabThera/Rituxan"]}],"arms":[{"label":"Rituximab","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.","primaryOutcome":{"measure":"Event-free Survival","timeFrame":"From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years","effectByArm":[{"arm":"Rituximab","deltaMin":53.944,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":21,"countries":["Hungary"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":124},"commonTop":["Diabetes mellitus"]}}